http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus Print Posted in:Legal RFEM’s Biosimilars Inter Partes Review (IPR) Dashboard By: C. Nichole Gifford Benjamin R. Holt RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar products. Tagged with: abatacept, adalimumab, Avastin®, bevacizumab, Enbrel®, etanercept, Featured, Herceptin®, Humira®, IPR, Legal, Natalizumab, Neulasta®, News, Orencia®, pegfilgrastim, PTAB, Rituxan®, Rituximab, trastuzumab, Tysabri®, USPTO See more Previous article PTAB Exercises its § 325(d) Discretion to Deny IPR of Piglet Vaccine Patent Back All Entries Next article USMCA Assailed as Exacerbating High Drug Prices
C. Nichole Gifford
Benjamin R. Holt